Literature DB >> 18513146

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

Marian Iwamoto1, Larissa A Wenning, Goutam C Mistry, Amelia S Petry, Sarah Y Liou, Kaylan Ghosh, Sheila Breidinger, Neal Azrolan, Maria J Gutierrez, William E Bridson, Julie A Stone, Keith M Gottesdiener, John A Wagner.   

Abstract

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18513146     DOI： 10.1086/588794

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  27 in total

1.  Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

Authors:  Risheng Cao; Yiqiao Hu; Yun Wang; Emily C Gurley; Elaine J Studer; Xuan Wang; Phillip B Hylemon; William M Pandak; Arun J Sanyal; Luyong Zhang; Huiping Zhou
Journal:  J Pharmacol Exp Ther       Date:  2010-05-14       Impact factor: 4.030

Review 2.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 3.  Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Authors:  Babafemi Taiwo; Robert L Murphy; Christine Katlama
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

4.  Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.

Authors:  Chloé Amouyal; Marion Buyse; Lea Lucas-Martini; Déborah Hirt; Laurent Genser; Adriana Torcivia; Jean-Luc Bouillot; Jean-Michel Oppert; Judith Aron-Wisnewsky
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

Review 5.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

7.  Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.

Authors:  Matthew L Rizk; Robert Houle; Grace Hoyee Chan; Mike Hafey; Elizabeth G Rhee; Xiaoyan Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

Review 8.  Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.

Authors:  Jamie D Croxtall; Susan J Keam
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

9.  Raltegravir pharmacokinetics during pregnancy.

Authors:  D Heather Watts; Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Tim R Cressey; Francesca Aweeka; Patty Lizak; Regis Kreitchmann; Sandra K Burchett; David E Shapiro; Elizabeth Hawkins; Elizabeth Smith; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-01       Impact factor: 3.731

10.  How Science Is Driving Regulatory Guidances.

Authors:  Xinning Yang; Jianghong Fan; Lei Zhang
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.